EGFR and triple-negative breast carcinoma: Given that 10% of triple-negative breast cancers harbor BRCA1/2 mutations [39], our results support consideration of the PBD-containing EGFR-targeted ADC (ABBV-321) within this specific subset of EGFR-expressing TNBC.